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2Dear Sir, 
According to World Health Organization (WHO), the incidence
ate of tuberculosis (TB) in Iran has decreased from 36/10 0,0 0 0
n 1990 to 17/10 0,0 0 0 in 2014 [1] . The main tasks performed by
inistry of Health of Iran for decreasing the incidence rate of TB,
specially in the last three decades include: starting the BCG vac-
ination in 1984, establishment of National TB Programme (NTP)
n 1996, conducting the Directly Observed Treatment, Short-Course
DOTS) strategy in 1997, performing TB control program in pris-
ns in 2002, using the electronic system for TB reporting in 2003,
stablishment of seven regional TB laboratories in the country dur-
ng 2010–2013 and free access to TB medication. However, one of
he important challenges for TB control strategies include the in-
reasing prevalence and rapid distribution of multidrug-resistant
B (MDR-TB) in Iran. Recently, this concern has been further in-
ensiﬁed by reports of extensively drug resistant (XDR) – and to-
ally drug resistant-TB (TDR-TB) [2] . According to the Iranian centre
or disease control and prevention, the number of conﬁrmed MDR-
B cases has increased from 8 in 2003 to 41 in 2015 [3] . Gener-
lly, patients infected with drug resistant strains of Mycobacterium
uberculosis need a long-term treatment and drugs with a higher
ost; the treatment cost proportion of Iranian MDR-TB patients to
rug-sensitive cases is roughly as 15,0 0 0–80,0 0 0 to 150 dollars;
he course of treatment proportion, 18–24 to 6 months; and hos-
italization rate proportion, 100 to 10 [3] . The increased preva-
ence of MDR-TB in Iran may have several reasons. Iran is an east-
rn Mediterranean country that located between the high MDR-
B (Pakistan, Azerbaijan and Armenia) and high-TB burden (Pak-
stan and Afghanistan) countries in the region. Based on the Ira-
ian centre for disease control and prevention, high rate of drug-
esistant cases was seen in border provinces of Iran i.e. Sistan–
aluchestan, Khorasan-Razavi, Golestan and East-Azerbaijan [2] .
istan-Baluchestan and Khorasan-Razavi are densely populated and
eriously affected in terms of economy and public health status.
dditionally, long borders (1500 km) with Afghanistan and Pak-
stan, have made these provinces a natural route for TB transmis-
ion. Regional laboratories with drug susceptibility testing capabil-
ty in these regions are still under quality control and do not have
roper facilities for patients admission. Consequently, local and im-
igrant patients with MDR-TB have to come to the central lab-
ratory for further treatment and hospitalization, which may in-
rease the risk of MDR-TB transmission in the country. Further-ttp://dx.doi.org/10.1016/j.jctube.2016.11.004 
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View publication statsore, prescription of inadequate treatment regimen, irregular drug
upply and poor drug quality have also been recently recognized
s other important risk factors for emergence of MDR-TB in Iran.
n addition to the above reasons, establishment of the nationwide
nternet-based reporting system may also have a role for the ob-
erved prevalence of MDR-TB. The ministry, set up a regulation re-
uiring all hospitals to report and refer suspected MDR-TB cases
o the national central laboratory for further investigation. As a re-
ult, the number of these cases and suspected cases reported by
ational laboratory has increased [3] . The development of better
nd more rapid diagnostic methods and continuous monitoring of
rug resistance are urgent priorities for the containment of MDR-
B in Iran. 
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